Home » Stocks » BBIO

BridgeBio Pharma, Inc. (BBIO)

Stock Price: $69.48 USD 3.04 (4.58%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 8.53B
Revenue (ttm) 21.95M
Net Income (ttm) -402.20M
Shares Out 118.17M
EPS (ttm) -4.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $69.48
Previous Close $66.44
Change ($) 3.04
Change (%) 4.58%
Day's Open 65.49
Day's Range 64.68 - 69.58
Day's Volume 587,804
52-Week Range 16.11 - 71.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced...

GlobeNewsWire - 1 week ago

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today...

The Motley Fool - 2 weeks ago

Here's why the biggest biotech IPO of 2019 outshines all its peers.

GlobeNewsWire - 2 weeks ago

PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Janu...

The Motley Fool - 2 weeks ago

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: EDIT, FATE
GlobeNewsWire - 2 weeks ago

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommend...

GlobeNewsWire - 1 month ago

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovation...

GuruFocus - 1 month ago

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarte...

Other stocks mentioned: ADPT, BSX, CNC, TMO
GlobeNewsWire - 1 month ago

Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise

GlobeNewsWire - 1 month ago

PALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Dece...

The Motley Fool - 1 month ago

This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.

GlobeNewsWire - 1 month ago

WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches...

GlobeNewsWire - 1 month ago

•  Application accepted under P riority R eview designation •  Application accepted into Real Time Oncology Review (RTOR) pilot program •  This is BridgeBio's s econd NDA a cceptance •  Applic...

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clin...

Seeking Alpha - 2 months ago

China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy com...

Zacks Investment Research - 2 months ago

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.03% and -52.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 2 months ago

-Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio's clinical and commercial development infrastructure to bear upon Eidos' Acoramidis 

GlobeNewsWire - 2 months ago

PALO ALTO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Nove...

Zacks Investment Research - 2 months ago

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of ...

GlobeNewsWire - 3 months ago

PALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to ...

GlobeNewsWire - 3 months ago

LA JOLLA and PALO ALTO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- The Salk Institute and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced a three-year collaboration agreement formed to ad...

The Motley Fool - 3 months ago

BridgeBio announced plans to fully acquire the biotech.

Other stocks mentioned: EIDX
Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...

Other stocks mentioned: EIDX
Invezz - 3 months ago

BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate...

Other stocks mentioned: EIDX
Market Watch - 3 months ago

BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for ...

Other stocks mentioned: EIDX
GlobeNewsWire - 3 months ago

BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own

Other stocks mentioned: EIDX
The Motley Fool - 3 months ago

These underappreciated biotechnology start-ups could turn heads one day -- but not yet.

Other stocks mentioned: AXGT, SIOX
Investors Business Daily - 3 months ago

BridgeBio Pharma said the FDA accepted its New Drug Application, the first NDA for the company, for its therapy to treat a rare, at times fatal, disease that often targets infants. BBIO rose.

GlobeNewsWire - 3 months ago

Application accepted under Priority Review designation with Breakthrough Therapy Designation and Rare Pediatric Disease Designation previously granted

GlobeNewsWire - 4 months ago

PALO ALTO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear gen...

GlobeNewsWire - 4 months ago

PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center ...

CNBC - 5 months ago

We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.

Other stocks mentioned: DBX, LITE, EL, JCOM, MRNA
GlobeNewsWire - 5 months ago

-Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020

GlobeNewsWire - 5 months ago

$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an eq...

GlobeNewsWire - 5 months ago

PHOENIX and SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Ivy Brain Tumor Center at Barrow Neurological Institute announced today that the first patient has been dosed in an investigato...

GlobeNewsWire - 6 months ago

SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with...

GlobeNewsWire - 6 months ago

BOSTON, July 10, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing...

GlobeNewsWire - 6 months ago

PALO ALTO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it ha...

GlobeNewsWire - 7 months ago

Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease Partnership to Leverage University of Florida’s Res...

GlobeNewsWire - 7 months ago

PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it ha...

GlobeNewsWire - 7 months ago

SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate ML Bio Solutions today announced that the first subject has been dosed in the Phase 1 clinica...

Kiplinger - 7 months ago

Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.

Other stocks mentioned: AMAT, BABA, GH, LLNW, PLUG, RVMD
GlobeNewsWire - 7 months ago

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical...

GlobeNewsWire - 8 months ago

BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 stu...

GlobeNewsWire - 8 months ago

Ended quarter with $928 million in cash, cash equivalents and marketable securities Ended quarter with $928 million in cash, cash equivalents and marketable securities

GlobeNewsWire - 8 months ago

PALO ALTO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference o...

GlobeNewsWire - 8 months ago

PALO ALTO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May...

Seeking Alpha - 9 months ago

Corona Anchor Series: BridgeBio Is A Secure Long-Term Investment

Zacks Investment Research - 9 months ago

BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

About BBIO

BridgeBio Pharma engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhi... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2019
CEO
Neil Kumar
Employees
369
Stock Exchange
NASDAQ
Ticker Symbol
BBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 63.75, which is a decrease of -8.25% from the latest price.

Price Target
$63.75
(-8.25% downside)
Analyst Consensus: Buy